Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 8
Abstract
Background: The objective of this study is to provide certain data on clinical outcomes and their predictors of traditional maximum androgen blockade (MAB) in prostate cancer with bone metastasis. Methods: Subjects were patients with prostate adenocarcinoma with bone metastasis initiated to treat with MAB as a primary treatment without any local therapy at our hospital between January 2003 and December 2010. Time to prostate specific antigen (PSA) progression, overall survival (OS) time, and association of clinical factors and outcomes were retrospectively evaluated. Results: A total of 57 patients were evaluable. The median age was 70 years. The median primary PSA was 203 ng/ml. Luteinizing hormone-releasing hormone agonists had been administered in 96.5% of the patients. Bicalutamide had been chosen in 89.4 % of the patients as the initial antiandrogen. The median time to PSA progression with MAB was 11.3 months (95% confidence interval [CI], 10.4 to 13.0). The median OS was 47.3 months (95% CI, 30.7 to 81.0). Gleason score 9 or greater, decline of PSA level equal to or higher than 1.0 ng/ml with MAB, and time to PSA nadir equal to or shorter than six months after initiation of MAB were independent risk factors for time to PSA progression (P=0.010, P=0.005, and P=0.001; respectively). Time to PSA nadir longer than six months was the only independent predictor for longer OS (HR, 0.255 [95% CI, 0.109 to 0.597]; P=0.002). Conclusions: Initial time to PSA nadir should be emphasized for clinical outcome analyses in future studies on prostate cancer with bone metastasis.
Authors and Affiliations
Yamamoto Y, Nozawa M, Itami Y, Kobayashi Y, Saito Y, Shimizu N, Minami T, Hayashi T, Tsuji H, Yoshimura K, Ishii T, Uemura H
Keywords
Related Articles
- EP ID EP551739
- DOI 10.14312/2052-4994.2013-30
- Views 61
- Downloads 0
Plant-based omega-3 stearidonic acid enhances antitumor activity of doxorubicin in human prostate cancer cell lines
Doxorubicin (DOX) is a first choice cytostatic drug in treatment of many cancers but among its side effects is cardiac toxicity. Stearidonic omega-3 fatty acid (SDA) has cardiac protective qualities and, therefore, we in...
Rapid tumor progression in a patient with HPV type 16 associated anal squamous cell carcinoma suffering from long-standing Crohn's disease: A case report
Background and aim: Squamous cell carcinoma (SCC) is the most common cancer of the anal region, typically associated with high-risk (hr) HPV infection. Furthermore, there is evidence that Crohn's disease predisposes to a...
Colorectal cancer: Ageing, myeloid-derived suppressor cells, and treatment: Report of two cases
Background: Colorectal cancer (CRC) is the third cause of cancer in the world and age is a risk factor for this disease. Treatments such as surgical resection and adjuvant chemotherapy have increased the mean survival an...
Structural imaging of the pancreas in rat using micro-CT: application to a non-invasivelongitudinal evaluation of pancreatic ductal carcinoma monitoring
The aim of the study was to evaluate the feasibility of a longitudinal non-invasive monitoring of rat pancreatic ductal adenocarcinoma (PDAC) using microCTscans (μCT). The identification of the pancreatic gland on (μCT)...
Economic evaluation of monoclonal antibody in the management of colorectal cancer
Objective: This study aims to determine the cost of colorectal cancer (CRC) management and compare the cost effectiveness of cetuximab and bevacizumab in the management of CRC. Method: This economic evaluation study from...